​Molina Healthcare: Best Buy in Managed Care

MoneyShow  |

I consider Molina Healthcare (MOH) to be the only undervalued growth stock among the eight largest health insurers; none of the other health insurers meet my investment criteria, either due to high P/Es or moderate earnings growth, notes Crista Huff, editor of Cabot Undervalued Stocks Advisor.

Last February I noted that the company had a huge earnings miss, with EPS bearing no resemblance to analysts' consensus earnings estimates.

I was apparently not the only investment professional who was alarmed at fourth quarter results, because on May 2, the company announced big changes in corporate leadership.

The CEO and CFO—who both happen to go by the surname of Molina—were ousted and experienced company and board executives were named in new leadership positions while the company searches for a permanent CEO.

New Chairman of the Board Dale Wolf immediately began instituting additional changes at the company, including a restructuring plan that focuses on multi-year cost savings, improved competitiveness in the Medicaid market, and presumably, a better handle on cash flow.

The market is now showing confidence in Wolf’s leadership; thus, it’s time to make a decision on whether to own the stock.

The company is expected to grow earnings per share (EPS) by 360% and 32.6% in 2017 and 2018.

The corresponding P/Es are 25.5 and 19.2, which are nicely below the earnings growth rates. The stock does not pay a dividend, and the debt levels are fair — not low and not high.

After selling Molina in February, I ignored the stock until this month, when I became quite impressed with the revised earnings outlook. Then, Morgan Stanley (MS) changed its recommendation from underweight to overweight.

I believe the share price on Molina is now completely out of the woods, and ready to begin marching back to its all-time high in the low $80’s, from the summer of 2015.

My recommendation is that traders and growth investors buy Molina, and don’t fret that you might have missed a couple of dollars on the share price. The worst is over, barring some very bad news or a big stock market correction.

My price target is $80, giving new investors a potential 33% capital gain. I’m adding Molina Healthcare to the “Buy Low Opportunities Portfolio” and rate the stock a Strong Buy.

Crista Huff is the lead analyst of Cabot Undervalued Stocks Advisor.

Subscribe to Crista Huff’s Cabot Undervalued Stocks Advisor here…

About : Founded in 1981, MoneyShow is a privately held financial media company headquartered in Sarasota, Florida. As a global network of investing and trading education, MoneyShow presents an extensive agenda of live and online events that attract over 75,000 investors, traders and financial advisors around the world.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer.

Companies

Symbol Name Price Change % Volume
MS Morgan Stanley 49.09 -0.06 -0.12 7,107,518 Trade
MOH Molina Healthcare Inc 121.91 -4.27 -3.38 547,223 Trade

Comments

Watchlist

Symbol Last Price Change % Change
AAPL

     
AMZN

     
HD

     
JPM

     
IBM

     
BA

     
WMT

     
DIS

     
GOOG

     
XOM

     
BRK.A

     
FB

     
JNJ

     
WFC

     
T

     
NFLX

     
TSLA

     
V

     
UNH

     
PG

     

World Economic Forum at Davos 2019 - Joseph Weinberg CEO PayCase, Chairman Shyft

Matt Bird sits down with Joseph Weinberg CEO PayCase, Chairman Shyft at the World Economic Forum at Davos 2019